GlassScriptPhysician profile
James Anthony Trippi
NPI 1164488037
$239,352.03
in general payments reported to CMS, 2019-2025
18 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $27K · 2021: $42K · 2022: $27K · 2023: $33K · 2024: $27K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Consulting Fee: $12K · Travel and Lodging: $4,936 · Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,915.50 |
| Consulting Fee | $11,755.00 |
| Travel and Lodging | $4,935.82 |
| Food and Beverage | $2,690.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $107,140.56 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $45,759.85 | 2019-2025 | Evkeeza |
| Amarin Pharma, INC. | $27,706.40 | 2019-2020 | |
| Esperion Therapeutics, INC. | $25,459.89 | 2020-2024 | Nexletol, Nexlizet |
| Ionis Pharmaceuticals, INC. | $15,407.07 | 2025 | Olezarsen, Tryngolza |
| Kaneka Medical America LLC | $12,403.25 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $3,241.63 | 2021-2024 | |
| Akcea Therapeutics, INC. | $1,820.00 | 2021 | |
| Heartflow, INC. | $121.95 | 2023 | Ffrct |
| Regeneron Pharmaceuticals, INC. | $96.73 | 2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $70.33 | 2019 | |
| Pfizer INC. | $44.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 2019 | |
| Amryt Pharma Holdings LTD | $18.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.37 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Trippi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.